Emergent BioSolutions
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Emergent BioSolutions generated cash of -$206,300,000, which is less than the previous year. Cash used in financing activities reached the amount of -$535,700,000 last year. Net change in cash is therefore -$530,900,000.
Cash Flow
| 2014 | 112.31M | -210.05M | 198.87M |
|---|---|---|---|
| 2015 | 44.45M | -45.46M | 33.44M |
| 2016 | 53.48M | -76.25M | -18.64M |
| 2017 | 208.13M | -249.93M | -51.40M |
| 2018 | 41.8M | -897.2M | 788.7M |
| 2019 | 188M | -96.9M | -35.9M |
| 2020 | 536M | -151M | 69.5M |
| 2021 | 321.1M | -225M | -141M |
| 2022 | -34.1M | -381.3M | 481.2M |
| 2023 | -206.3M | 212.3M | -535.7M |
EBS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 642.6M | 576.3M | 621.5M | 168M | 112.4M | 179.3M | 271.51M | 312.79M | 280.49M | 179.33M |
Operating activities | ||||||||||
Net income | -760.5M | -223.8M | 230.9M | 305.1M | 54.5M | 62.7M | 82.59M | 51.77M | 62.87M | 36.74M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 125.1M | 143.3M | 123.8M | 114.5M | 110.7M | 62.2M | 42.57M | 38.22M | 35.33M | 32.45M |
Stock-based compensation expense | 23.1M | 45.1M | 42.4M | 51.8M | 26.7M | 0 | 15.21M | 18.47M | 15.84M | 12.82M |
| Deferred income tax benefit | 23.1M | 45.1M | 42.4M | 51.8M | 26.7M | 0 | 15.21M | 18.47M | 15.84M | 12.82M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -21.6M | 114.7M | -48.2M | 49M | -8.2M | -94.2M | -4.81M | -22.44M | -64.35M | 21.40M |
Inventories | 600K | -51.9M | -44M | -83.2M | -16.7M | -1.9M | 6.06M | -9.02M | -11.26M | 4.22M |
Accounts payable | 10.6M | -14M | -2.5M | 19.8M | 16.5M | -7M | 16.13M | -14.79M | 4.74M | -9.27M |
Cash generated by operating activities | -206.3M | -34.1M | 321.1M | 536M | 188M | 41.8M | 208.13M | 53.48M | 44.45M | 112.31M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -51.6M | -115.8M | -225M | -141M | -86.9M | -72.1M | -54.82M | -76.25M | -44.81M | -30.67M |
Acquisitions Net | 270.2M | 0 | 0 | 0 | 0 | -827.7M | -195.1M | 0 | -650K | -179.37M |
Cash generated by investing activities | 212.3M | -381.3M | -225M | -151M | -96.9M | -897.2M | -249.93M | -76.25M | -45.46M | -210.05M |
Financing activities | ||||||||||
Common Stock Issued | 8.4M | 0 | 15.9M | 31.6M | 8.19M | 15.9M | 0 | 17.12M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -82.1M | -119.8M | -13.8M | -7.4M | -100K | -33.1M | -1.1M | -100K | -200K |
Repayments of term debt | -543.4M | 564.2M | -35.9M | -387.1M | 13.7M | -2.8M | -20M | 0 | 2M | -62M |
Cash used in financing activities | -535.7M | 481.2M | -141M | 69.5M | -35.9M | 788.7M | -51.40M | -18.64M | 33.44M | 198.87M |
Net Change In Cash | -530.9M | 66.3M | -45.2M | 453.5M | 55.6M | -66.9M | -93.22M | -41.28M | 32.29M | 101.16M |
Cash at end of period | 111.7M | 642.6M | 576.3M | 621.5M | 168M | 112.4M | 178.29M | 271.51M | 312.79M | 280.49M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |